Press Releases
You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Asarina Pharma obtains convertible loan for continued research on neurological conditions including Obsessive Compulsive Disorder
2021-05-31 18:00
Regulatory
The convertible loan supplements Asarina Pharma’s current financial resources and will be spent on further exploration of the potential of Sepranolone...
Each warrant gives the holder the right to subscribe to one new Asarina share at a fixed price of SEK 9.87 (150% of the average share price during the...
With Cognitive Behavioral Therapy as first-line treatment for Tourette, and many pharma treatments exhibiting severe side effects, there is a large unmet...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME For further information, please contact: Peter Nordkild, CEO Phone: +45 25...
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2020...
Due to the extraordinary situation resulting from the covid-19 pandemic, the Company encourages shareholders to exercise their voting rights at the AGM...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME (TS) MENSTRUAL MIGRAINE (MM) PREMENSTRUAL DYSPHORIC DISORDER (PMDD) For further information...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME For further information, please contact: Peter Nordkild, CEO Phone: +45 25...
New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
2021-02-11 18:32
Regulatory
Professor Marco Bortolato presented the new preclinical findings at the “Allopregnanolone and its synthetic analogues: from bench to clinical strategies...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS For further information, please contact: Peter Nordkild, CEO Phone: +45 25 47 16 46 E-mail: peter.nordkild@asarinapharma.com...